AMC 010: pretreatment characteristics
Variable . | R-CHOP, no. (%) . | CHOP, no. (%) . | Total, no. (%) . |
|---|---|---|---|
| Age, y | 43.5 (26-69)* | 40 (26-73)* | 42 (26-73)* |
| Homosexual male | 65 (65) | 29 (57) | 94 (63) |
| Injection drug use | 11 (11) | 7 (14) | 18 (12) |
| Heterosexual contact | 19 (19) | 15 (29) | 34 (23) |
| Other risk group | 13 (13) | 8 (16) | 21 (14) |
| CD4 level, cells/mm3 | 130 (1-2457)† | 147 (2-986)† | 133 (1-2457)† |
| CD4 level less than 50 cells/mm3 | 22 (25) | 11 (22) | 33 (24) |
| CD4 level more than 200 cells/mm3 | 29 (33) | 16 (33) | 45 (33) |
| Prior opportunistic infection | 36 (36) | 15 (29) | 51 (34) |
| Stage III/IV | 79 (80) | 40 (78) | 119 (79) |
| Elevated LDH | 39 (39) | 24 (47) | 63 (42) |
| KPS, % | |||
| 100 | 26 (26) | 19 (37) | 45 (30) |
| 80/90 | 55 (56) | 17 (33) | 72 (48) |
| 60/70 | 17 (17) | 15 (29) | 32 (21) |
| 40/50 | 1 (1) | 0 (0) | 1 (1) |
| IPI score (age-adjusted) | |||
| 0 | 14 (14) | 6 (12) | 20 (13) |
| 1 | 42 (42) | 18 (35) | 60 (40) |
| 2 | 35 (35) | 20 (39) | 55 (37) |
| 3 | 8 (8) | 7 (14) | 15 (10) |
| Prior antiretrovirals | |||
| None | 26 (26) | 21 (41) | 47 (31) |
| Any 3 drugs | 66 (67) | 27 (53) | 93 (62) |
| Protease inhibitor | 58 (59) | 24 (48) | 82 (55) |
| Histology | |||
| Diffuse large B cell | 80 (81) | 40 (78) | 120 (80) |
| Burkitt | 8 (8) | 6 (12) | 14 (9) |
| HG NHL NOS | 4 (4) | 5 (10) | 9 (6) |
| Other | 7 (7) | 0 (0) | 7 (5) |
Variable . | R-CHOP, no. (%) . | CHOP, no. (%) . | Total, no. (%) . |
|---|---|---|---|
| Age, y | 43.5 (26-69)* | 40 (26-73)* | 42 (26-73)* |
| Homosexual male | 65 (65) | 29 (57) | 94 (63) |
| Injection drug use | 11 (11) | 7 (14) | 18 (12) |
| Heterosexual contact | 19 (19) | 15 (29) | 34 (23) |
| Other risk group | 13 (13) | 8 (16) | 21 (14) |
| CD4 level, cells/mm3 | 130 (1-2457)† | 147 (2-986)† | 133 (1-2457)† |
| CD4 level less than 50 cells/mm3 | 22 (25) | 11 (22) | 33 (24) |
| CD4 level more than 200 cells/mm3 | 29 (33) | 16 (33) | 45 (33) |
| Prior opportunistic infection | 36 (36) | 15 (29) | 51 (34) |
| Stage III/IV | 79 (80) | 40 (78) | 119 (79) |
| Elevated LDH | 39 (39) | 24 (47) | 63 (42) |
| KPS, % | |||
| 100 | 26 (26) | 19 (37) | 45 (30) |
| 80/90 | 55 (56) | 17 (33) | 72 (48) |
| 60/70 | 17 (17) | 15 (29) | 32 (21) |
| 40/50 | 1 (1) | 0 (0) | 1 (1) |
| IPI score (age-adjusted) | |||
| 0 | 14 (14) | 6 (12) | 20 (13) |
| 1 | 42 (42) | 18 (35) | 60 (40) |
| 2 | 35 (35) | 20 (39) | 55 (37) |
| 3 | 8 (8) | 7 (14) | 15 (10) |
| Prior antiretrovirals | |||
| None | 26 (26) | 21 (41) | 47 (31) |
| Any 3 drugs | 66 (67) | 27 (53) | 93 (62) |
| Protease inhibitor | 58 (59) | 24 (48) | 82 (55) |
| Histology | |||
| Diffuse large B cell | 80 (81) | 40 (78) | 120 (80) |
| Burkitt | 8 (8) | 6 (12) | 14 (9) |
| HG NHL NOS | 4 (4) | 5 (10) | 9 (6) |
| Other | 7 (7) | 0 (0) | 7 (5) |